Trial reportBritish journal of clinical pharmacology2013
A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.
Trial report in British journal of clinical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 186 citations in OpenAlex.
- Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: a systematic literature review and network meta-analysis.Journal of comparative effectiveness research · 2026Pooled it
- A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa.British journal of clinical pharmacology · 2024Trial
- Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.Journal of acquired immune deficiency syndromes (1999) · 2013Trial
- Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study.AIDS (London, England) · 2013Trial
- A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.British journal of clinical pharmacology · 2013Trial
- Overview of pseudo-acute kidney injury.Renal failure · 2026Review
- Virological and metabolic outcomes after switching to dolutegravir or rilpivirine in virologically suppressed adults with HIV in Thailand: an open-label, randomised, controlled, non-inferiority trial.The Lancet regional health. Southeast Asia · 2026Article
- Article
- Exploring the impact of Cabotegravir-Rilpivirine long-acting on weight gain, body composition and quality of life in adults living with HIV.HIV medicine · 2026Article
- Efficacy of Dolutegravir Plus Lamivudine in People With TB/HIV Co-Infection Using a Rifampicin or Rifabutin-Based Regimen: A Retrospective Observational Case Series.Immunity, inflammation and disease · 2026Observational
- Biomarkers influence kidney function estimates more so than race among persons with HIV.AIDS research and therapy · 2025Article
- Hidden risks of first-line regimen switching in antiretroviral therapy-treated patients.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2025Article
- Prevalence and risk factors of adverse drug events with dolutegravir-based regimens among Thai people living with HIV: a retrospective cohort study.AIDS research and therapy · 2025Article
- Decline in estimated glomerular filtration rate following substitution of Nevirapine-based regimen with Tenofovir-based regimen in Indonesia.BMC infectious diseases · 2025Observational
- Impaired creatinine-based estimated glomerular filtration rate in Thai individuals switching to dolutegravir: illustrating the role of cystatin C testing to aid clinical decision making.AIDS research and therapy · 2025Observational
- Effects of Cimetidine and Dolutegravir on the Endogenous Drug-Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers.Clinical pharmacology and therapeutics · 2025Article
- Efficacy and safety of dolutegravir plus lamivudine for patients with late presentation of HIV-1 infection: a retrospective real-world cohort study in Southwest China.Frontiers in medicine · 2025Article
- An Integrated Approach for Representing Knowledge on the Potential of Drugs to Cause Acute Kidney Injury.Drug safety · 2025Article
- The Metabolism of Creatinine and Its Usefulness to Evaluate Kidney Function and Body Composition in Clinical Practice.Biomolecules · 2025Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimDolutegravir (DTG; S/GSK1349572) is under clinical development as a once daily, unboosted integrase inhibitor for the treatment of HIV infection. The effect of DTG on glomerular filtration rate (GFR), effective renal plasma flow (ERPF), and creatinine clearance (CLcr ) was evaluated in 34 healthy volunteers.
methodsSubjects received DTG 50 mg (once daily or twice daily) or placebo for 14 days. GFR was measured by iohexol plasma clearance, ERPF was assessed by para-aminohippurate plasma clearance and CLcr was measured by 24 h urine collection.
resultsAll treatments were generally well tolerated. A modest decrease (10-14%) in CLcr was observed, consistent with clinical study observations. DTG 50 mg once daily and twice daily had no significant effect on GFR or ERPF compared with placebo over 14 days in healthy subjects.
conclusionsThese findings support in vitro data that DTG increases serum creatinine by the benign inhibition of the organic cation transporter 2, which is responsible for tubular secretion of creatinine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.